Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study.

ABSTRACT:

Background

Flumatinib is a novel second-generation tyrosine kinase inhibitor (2G-TKI), which was approved in November 2019 in China. A previous phase III study evaluated the efficacy and safety of flumatinib as a first-line therapy for patients with chronic phase chronic myeloid leukemia (CML-CP). However, randomized trials comparing flumatinib with other 2G-TKIs remain lacking.

Objectives

To assess the efficacy and safety of flumatinib versus nilotinib as a first-line treatment for CML-CP.

Design

A multicenter retrospective study.

Methods

We retrospectively analyzed 101 and 64 patients treated with flumatinib and nilotinib during the same period, respectively.

Results

Patients in the flumatinib group were significantly older than patients in the nilotin

SUBMITTER: Lei Y 

PROVIDER: S-EPMC12041721 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature